Protocol No.: D926XC00001

TROPION-Breast03: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-Negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy
Principal Investigator
Safi, Danish
Phase
III
Age Group
Adult
Applicable Disease Site
Breast Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Emily Hawkins, BSN
Research Nurse
Phone: +1 304-293-7375

View on ClinicalTrials.gov